Robeco Institutional Asset Management B.V. Purchases 1,053,482 Shares of Pfizer Inc. (NYSE:PFE)

Robeco Institutional Asset Management B.V. raised its position in Pfizer Inc. (NYSE:PFE) by 16.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,431,299 shares of the biopharmaceutical company’s stock after buying an additional 1,053,482 shares during the period. Robeco Institutional Asset Management B.V. owned 0.13% of Pfizer worth $188,309,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. Beam Wealth Advisors Inc. increased its holdings in Pfizer by 1.5% during the 4th quarter. Beam Wealth Advisors Inc. now owns 27,444 shares of the biopharmaceutical company’s stock valued at $728,000 after purchasing an additional 401 shares in the last quarter. Providence Capital Advisors LLC grew its holdings in shares of Pfizer by 0.4% during the fourth quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company’s stock worth $3,034,000 after purchasing an additional 409 shares during the last quarter. Donaldson Capital Management LLC increased its stake in shares of Pfizer by 1.2% in the fourth quarter. Donaldson Capital Management LLC now owns 35,694 shares of the biopharmaceutical company’s stock valued at $947,000 after buying an additional 410 shares in the last quarter. Noesis Capital Mangement Corp raised its holdings in shares of Pfizer by 2.6% in the fourth quarter. Noesis Capital Mangement Corp now owns 16,357 shares of the biopharmaceutical company’s stock valued at $434,000 after buying an additional 413 shares during the last quarter. Finally, First Command Advisory Services Inc. lifted its position in Pfizer by 2.5% during the 4th quarter. First Command Advisory Services Inc. now owns 17,479 shares of the biopharmaceutical company’s stock worth $464,000 after buying an additional 418 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

Pfizer stock opened at $24.29 on Thursday. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $138.10 billion, a P/E ratio of 17.60, a PEG ratio of 0.88 and a beta of 0.57. The business has a 50-day moving average of $23.38 and a 200-day moving average of $24.87. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to analysts’ expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business’s revenue for the quarter was down 7.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.82 earnings per share. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.08%. Pfizer’s payout ratio is presently 124.64%.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Citigroup restated a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. UBS Group boosted their target price on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 30th. Finally, Cantor Fitzgerald started coverage on Pfizer in a research note on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price target on the stock. One analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.